Storia in 9 fonti

CVS expands access to blockbuster weight-drugs in surprise reversal

This move marks a pivotal shift for patients seeking access to these highly sought-after treatments

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

independent.co.ukStai leggendo8 h fa

CVS expands access to blockbuster weight-drugs in surprise reversal

This move marks a pivotal shift for patients seeking access to these highly sought-after treatments

originale

Timeline cronologica

giovedì 28 maggio 2026·biopharmadive.com
CVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
giovedì 28 maggio 2026·nbcnews.com
CVS Caremark will cover Lilly’s weight loss drug Zepbound once again
The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.

cnbc.com

13 h fa

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Leggi questa versione → originale

nbcnews.com13 h fa

CVS Caremark will cover Lilly’s weight loss drug Zepbound once again

The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.

Leggi questa versione → originale

qz.com12 h fa

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

Leggi questa versione → originale

upi.com6 h fa

CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.

Leggi questa versione → originale

biopharmadive.com23 h fa

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

Leggi questa versione → originale

giovedì 28 maggio 2026·

morningstar.com

CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options

giovedì 28 maggio 2026·

cnbc.com

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

giovedì 28 maggio 2026·

qz.com

CVS Caremark adds Zepbound and Foundayo to formulary

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

giovedì 28 maggio 2026·

independent.co.uk